Expert study designs, in vitro ADME assays and data interpretation from the in vitro ADME services group at Charles River allow you to characterize your drug candidate's ADME properties and its potential for drug interactions.
Charles River has focused on building efficient systems and procedures to meet the needs and timelines of clients working in the drug discovery environment. Many of our in vitro assays have multiple formats available to suit the different stages of the drug discovery pipeline, allowing us to offer a flexible approach to our ADME services. We offer a range of study design levels (SDLs) in our in vitro assay services. Each of our in vitro assays can be offered as an early screening (single time point or concentration) or a more definitive (IC50 or T1/2) study to estimate PK/ADME characteristics.
In vitro ADME assays are an important part of a successful drug development program aiding in the critical decision making process by offering metabolic information about drug-drug interactions, pharmacokinetics, absorption and potential toxicities. Our wide range of automated in vitro assays can be performed under GLP conditions, if required, yielding information in the areas of metabolism, toxicity and physicochemical characteristics.
While Charles River has standard procedures for each of these assays listed below, our team of experienced study directors can also assist in designing the best strategy and protocols customized to suit any drug discovery need.
- Human liver microsomes or recombinant enzymes
- Major CYP450 isozymes: 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4 and 2E1
- Reversible, metabolic and time-dependent inhibition (IC50 shift)
- Initial screening assessments (% inhibition) or definitive determinations (IC50, Ki)
- Kinact/KI determinations
- Determine formation of MIC and/or covalent binding
- Activity of CYP450 isoforms measured via LC-MS/MS analysis
- Drug-drug interaction experiments